The immunosuppression and potential for EBV reactivation of fludarabine combined with cyclophosphamide and dexamethasone in patients with lymphoproliferative disorders
- 24 December 1999
- journal article
- research article
- Published by Wiley in British Journal of Haematology
- Vol. 107 (4) , 877-882
Abstract
Fludarabine is effective in chronic lymphocytic leukaemia (CLL) and low‐grade non‐Hodgkin's lymphoma (NHL). A major side‐effect of this purine analogue is immunosuppression which may favour opportunistic infections. Additionally, impairment of immunosurveillance might promote Epstein‐Barr virus (EBV) reactivation and possibly favour transformation to high‐grade malignancy. The aim of this study was to evaluate the immunosuppression‐related effects of the fludarabine‐based combination Flucyd in advanced low‐grade NHL or CLL by serially monitoring T‐lymphocyte subsets, opportunistic infections, EBV‐reactivation, and histologic transformation. 24 patients with advanced NHL (n = 21) or CLL (n = 3) received fludarabine 25 mg/m2/d + cyclophosphamide 350 mg/m2/d + dexamethasone 20 mg/d in 3 d courses for a maximum of six courses. The overall response rate was 79% (eight CR, 11 PR, five failures); 11 patients relapsed or progressed between 3 and 19 months from response, and eight are in CR or PR at 3–27 months. The CD4+ lymphocyte counts decreased significantly during therapy from a median of 484/μl pre‐treatment (range 142–1865) to a median of 198/μl (71–367). In 19 responders monitored off therapy every 3 months until relapse/progression, CD4+ counts were persistently low with minimal recovery over time. During treatment, 16 infections occurred in 11/24 patients. No delayed opportunistic infections occurred in responders while off therapy. The circulating EBV DNA load serially measured in 19 patients by a quantitative PCR assay showed an increase in four patients during treatment. A lymph node biopsy performed in two of these was PCR positive for EBV DNA, whereas LMP1 and EBERs were negative. Six NHL patients evolved into high‐grade B‐cell NHL. In conclusion, fludarabine combined with cyclophosphamide and dexamethasone is an effective therapy for recurrent indolent lymphoma. This combination produces prolonged T‐lymphocytopenia and has the potential to reactivate a latent EBV infection. T‐cell dysfunction, however, is not associated with higher incidence of clinical opportunistic infections and does not adversely influence clinical outcome.Keywords
This publication has 23 references indexed in Scilit:
- Epstein–Barr Virus–Associated Lymphoma after Treatment of Macroglobulinemia with CladribineNew England Journal of Medicine, 1999
- Lymphoproliferative disorders involving Epstein-Barr virus after hemopoietic stem cell transplantationCurrent Opinion in Oncology, 1999
- A case of EBV-associated lymphoproliferative disease following high-dose therapy and CD34-purified autologous peripheral blood progenitor cell transplantationBone Marrow Transplantation, 1998
- Epstein–Barr virus-associated lymphoproliferative disorder after autologous bone marrow transplantation: report of two casesBone Marrow Transplantation, 1998
- Epstein‐Barr virus associated B‐cell lymphoma after autologous bone marrow transplantation for T‐cell acute lymphoblastic leukaemiaBritish Journal of Haematology, 1997
- Progressive loss of CD8+ T cell-mediated control of a gamma-herpesvirus in the absence of CD4+ T cells.Journal of Experimental Medicine, 1996
- Early identification of Epstein‐Barr virus‐associated post‐transplantation lymphoproliferative diseaseBritish Journal of Haematology, 1995
- Clinical Experience with Fludarabine and its Immunosuppressive Effects in Pretreated Chronic Lymphocytic Leukemias and Low-Grade LymphomasLeukemia & Lymphoma, 1995
- Quantification of human cytomegalovirus DNA in peripheral blood polymorphonuclear leukocytes of immunocompromised patients by the polymerase chain reactionJournal of Virological Methods, 1993
- Cancers Complicating Organ TransplantationNew England Journal of Medicine, 1990